Skip to content
GHIAA Logo Small
Envelope
Linkedin-in
Twitter
  • Home
  • Our Work
    • GHIAA
    • MAPGuide
  • About
    • About GHIAA
    • Team
  • News
  • Resources
    • Useful Links
  • Contact
  • search
Menu
  • Home
  • Our Work
    • GHIAA
    • MAPGuide
  • About
    • About GHIAA
    • Team
  • News
  • Resources
    • Useful Links
  • Contact
  • search
 
search

IMI 2 Joint Undertaking Model Consortium Agreement

  • Post author:GHIAA Admin
  • Post published:June 22, 2021
  • Post category:

Continue Reading IMI 2 Joint Undertaking Model Consortium Agreement

IMI 2 Model Consortium Agreement & Model Grant Agreement

  • Post author:Loren
  • Post published:May 23, 2020
  • Post category:

Continue Reading IMI 2 Model Consortium Agreement & Model Grant Agreement

IMI 2 Joint Undertaking Model Consortium Agreement

  • Post author:Loren
  • Post published:May 23, 2020
  • Post category:

Continue Reading IMI 2 Joint Undertaking Model Consortium Agreement

IMI 2 Joint Undertaking Model Consortium Agreement

  • Post author:Loren
  • Post published:May 23, 2020
  • Post category:

Continue Reading IMI 2 Joint Undertaking Model Consortium Agreement

IMI 2 Model Consortium Agreement & Model Grant Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading IMI 2 Model Consortium Agreement & Model Grant Agreement

IMI 2 Joint Undertaking Model Consortium Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading IMI 2 Joint Undertaking Model Consortium Agreement

IMI 2 Joint Undertaking Model Consortium Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue Reading IMI 2 Joint Undertaking Model Consortium Agreement

CARB-X Research Subaward Agreement

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue Reading CARB-X Research Subaward Agreement

IMI 2 Model Grant Agreement

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue Reading IMI 2 Model Grant Agreement
  • 1
  • 2
  • Go to the next page

Recent Posts

  • MAPGuide Glossary (DRAFT)
  • Key Terms of Alliance Agreements

Recent Comments

    Archives

    • May 2020

    Categories

    • Resource & Analysis

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    Get In Touch

    info@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    Our Work
    MAPGuide
    About GHIAA
    Team
    News
    Useful Links
    COVID19

    Contact Us

    Get In Touch

    info@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    GHIAA
    MAPGuide
    About GHIAA
    Team
    News
    Links
    COVID19

     

    Twitter
    Linkedin-in

    info@ghiaa.org

    Privacy Policy

    • Privacy Policy
    • Join
    Menu
    • Privacy Policy
    • Join

    © 2021 Global Health Innovation Alliance Accelerator. All Rights Reserved

    Sign Up to Our Newsletter

    Receive updates about GHIAA’s latest tools, resources and news.

    I consent to receiving email updates from GHIAA and have read and agree to the Privacy Policy and Terms of Service..

    Select Technology

    • Any Technologies
    • Device
    • Diagnostic
    • Drug
    • Vaccine

    Select Partner Type

    • Any Partner types
    • Academic institution
    • Biotechnology company
    • Contract research organization
    • Funder
    • General Industry
    • Government
    • Multilateral organization
    • Multinational pharmaceutical company
    • Other nonprofit
    • Pharmaceutical manufacturer
    • Product development partnership
    • Vaccine manufacturer

    Select Development Stage

    • Any Develoment stages
    • Discovery/Concept
    • Preclinical
    • Early clinical (through Phase 2)
    • Late clinical (Phase 3)
    • Commercialization
    • Field Testing

    Select Issue or Sub-issues

    • Access to medicines
      • All Access to medicines
      • Donation
      • Equitable access
      • Funder step-in rights
      • Outbreak preparedness
      • Pandemic Products
      • Affordable or reasonable pricing
      • Public health licenses
      • Supply/Purchase of Products
    • Annexes
      • All Annexes
      • Commercialization strategy
      • Global access plans
    • Business model
      • All Business model
      • Benefit/revenue sharing
      • Payment Structures
    • Consortium structure & management
      • All Consortium structure & management
      • Reporting Requirements
      • Roles & Responsibilities
    • Information sharing & data safety
      • All Information sharing & data safety
      • Confidentiality
      • Data management
      • Exceptions and limitations to the confidentiality obligations
      • Information sharing
      • Material transfer
      • Technology transfer
    • IP ownership & licensing
      • All IP ownership & licensing
      • Access to results
      • Exceptions or limitations to the IP ownership rules
      • Exploitation of results
      • Ownership of background IP
      • Ownership of results
      • Protection of results
      • Sublicenses
      • Use of background IP
    • Liability
      • All Liability
      • Indemnity / indemnification
      • Insurance
      • Limitation of liability/damage
      • Representations & Warranties
    • Open sciences & open data
      • All Open sciences & open data
      • Open data
      • Open sciences
      • Publication
    • Other
      • All Other
      • Conflict of Interest
      • Dispute resolution
      • Regulatory strategy
      • Survival
    • Term & termination
      • All Term & termination
      • Effect of termination
      • Term of agreement
      • Termination & withdrawal